Overview
Representative Matters
Insights

Thomas represents public and private companies on a wide range of matters, including securities issuances, securities law compliance, periodic reporting, mergers and acquisitions and general corporate governance. He also regularly advises clients with respect to the Corporate Transparency Act.

Thomas maintains an active pro bono practice. He frequently counsels aspiring nonprofit organizations from formation through application for recognition of federal tax exemption, and with ongoing governance and related matters.

  • Represented a publicly traded specialty pharmaceutical company in its $200 million private investment in public equity (PIPE) transaction.
  • Represented a publicly traded specialty pharmaceutical company in its establishment of an at-the-market program for selling its common stock.
  • Represented a publicly traded real estate investment trust in its $550 million underwritten public offering of senior notes.
  • Represented a UK-based trenchless rehabilitation manufacturer in the sale of its U.S. business.
  • Represented a publicly traded owner/operator of franchised businesses in a go-private transaction.
  • Represented a private equity portfolio company in the acquisition of drug testing services businesses.
  • Represented private equity fund portfolio companies in connection with various day to day business matters, including corporate governance, financing, contract, and executive compensation matters.

Thomas represents public and private companies on a wide range of matters, including securities issuances, securities law compliance, periodic reporting, mergers and acquisitions and general corporate governance. He also regularly advises clients with respect to the Corporate Transparency Act.

Thomas maintains an active pro bono practice. He frequently counsels aspiring nonprofit organizations from formation through application for recognition of federal tax exemption, and with ongoing governance and related matters.

  • Represented a publicly traded specialty pharmaceutical company in its $200 million private investment in public equity (PIPE) transaction.
  • Represented a publicly traded specialty pharmaceutical company in its establishment of an at-the-market program for selling its common stock.
  • Represented a publicly traded real estate investment trust in its $550 million underwritten public offering of senior notes.
  • Represented a UK-based trenchless rehabilitation manufacturer in the sale of its U.S. business.
  • Represented a publicly traded owner/operator of franchised businesses in a go-private transaction.
  • Represented a private equity portfolio company in the acquisition of drug testing services businesses.
  • Represented private equity fund portfolio companies in connection with various day to day business matters, including corporate governance, financing, contract, and executive compensation matters.

Top areas of focus

Education

  • University of Virginia School of Law, J.D., 2020
  • Emory University, B.A., with highest honors, 2011, Phi Beta Kappa

Bar Admissions

  • Virginia